Figure 1.

MIR210HG expression and its correlation with pancreatic cancer prognosis (a) The expression of lncRNA MIR210HG between GTEx normal pancreas (n = 171) and GDC-TCGA-PAAD tumour samples (n = 179), according to The Genotype-Tissue Expression (GTEx) project and TCGA-PAAD database. logFC = 2.820. p-value = 5.06E-17. (b) The expression of lncRNA MIR210HG in pancreatic cancer and normal pancreatic tissues, according to GSE16515. LogFC = 1.837, p-value = 4.04E-09. (c) Cases from the GDC-TCGA-PAAD database were divided into two groups using the 0.5 cut-off of MIR210HG expression. The correlation between MIR210HG expression and the overall survival in patients with pancreatic cancer was analysed. (samples having an OS-time of less than 1 month were discarded from analysis to exclude other disease burdens caused death). (d) The expression of lncRNA MIR210HG in the normal pancreatic duct, IPMN-adenoma, IPMN-carcinoma, and invasive cancer originating in IPMN, according to GSE19650. IPMN-adenoma, logFC = 0.068, p-value = 8.89E-01, IPMN-carcinoma logFC = 1.545, p-value = 6.35E-03, invasive cancer originating in IPMN logFC = 2.012, p-value = 4.29E-03, compared to normal pancreatic duct. (e) The expression of lncRNA MIR210HG was examined in 20 paired pancreatic cancer and adjacent non-cancerous tissue samples using RT-qPCR. (f) The expression of lncRNA MIR210HG was examined in a normal hTERT-HPNE cell line and four pancreatic cancer cell lines, Panc-1, BxPC-3, AsPC-1, and MIA PaCa-2, using RT-qPCR. *P< 0.05, **P< 0.01